Phase Forward to Exhibit, Present Sessions on EDC and Data Repositories

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 20, 2009--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate in the 12^th Annual Drug Information Association (DIA) Workshop for Clinical Data Management, January 29-30 at the Tower Hall Funabori in Tokyo, Japan.

On Thursday, January 29, at 4:45 p.m. local time, company CTO Tim Rochford will discuss "Repository Families: Avoiding Dysfunctional Relationships." Mr. Rochford will contrast essential design requirements of cross-repository analysis activities with affordances offered by underlying technology approaches.

Vice president of global CRO partnerships, Mike Davies will lead a session titled, "Building a Strong EDC Foundation through the Power of Partnership" on Friday, January 30, at 4:30 p.m. local time. Leveraging customer data and experiences, Mr. Davies will discuss how the role of EDC, from technology to services, evolves over time and the critical role partnerships play to success.

The company will also showcase its EDC, safety management, Phase I and interactive response technologies at booths 7 and 8.

Members of the media interested in speaking with Phase Forward at this event should contact Maria Sumner at +44 1628 640743 or maria.sumner@phaseforward.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), phase I clinic automation (LabPas(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (Empirica Signal(TM)) and Signal Management, adverse event reporting (Empirica Trace(TM)), applied data standards (WebSDM(TM)) and Web-integrated interactive response technologies (Clarix(TM)). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

CONTACT: Phase Forward
Maria Sumner, +44 1628 640743
maria.sumner@phaseforward.com

Source: Phase Forward